BKS-112 is a potent, selective histone deacetylase 6 (HDAC6) inhibitor with IC50 of 42.98 nM, 126-fold selective over HDAC1.
BKS-112 exhibits selective cytotoxicity toward cancer cells while showing significantly reduced toxicity in MCF-10A normal cells.
BKS-112 exhibits selective cytotoxicity toward cancer cells while showing significantly reduced toxicity in MCF-10A normal cells.
BKS-112 (50 uM) significant increases the expression of acetylated histones in MDA-MB-231 cells.
BKS-112 reduces cell migration, demonstrating anti-metastatic potential, induces G1 phase cell cycle arrest and modulates key regulators, including cyclins and cyclin-dependent kinases (CDKs).
BKS-112 also elevatesreactive oxygen species (ROS) levels, affecting apoptosis-related PI3K/AKT signaling, triggers autophagy by upregulating LC3 and Atg-7 expression.
